Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvant This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including: $500 million upfront payment Approximately $70 million equity investment in Novavax Up to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royaltie ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co- commercialize the company's Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. The licensing agreement will allow Novavax to lift its "going concern" warni ...

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enhanced conveni ...

Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit ...

High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%. Since the page turned to 2023 a little over 16 months ago, the bulls have been running wild on Wall Street. Professional and everyday investors have flocked to high-growth, innovation-driven businesses, and have been particularly enamored with Wall Street's next-big-thing investment trend: artificial intelligence (AI). With AI and machine learning, software and systems are given the abili ...

Novavax (NVAX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may mov ...

GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows: Conference call details: Date: May 10, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3VNP8J5 Dial-in number: (888) 664-6383 (D ...

Highlights Novavax's Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company's Other Proposals at the Annual Meeting RALEIGH, N.C., May 06, 2024 ( ...

In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day. This move outpaced the S&P 500's daily loss of 1.57%. Elsewhere, the Dow saw a downswing of 1.49%, while the tech-heavy Nasdaq depreciated by 2.04%. Shares of the vaccine maker have depreciated by 7.74% over the course of the past month, underperforming the Medical sector's loss of 6.09% and the S&P 500's loss of 2.5%. The upcoming earnings release of Novavax will be of great interest to investors. Th ...

Is there still too much risk surrounding this business? In just the past 12 months, Novavax (NVAX 0.94%) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to market, and now with some concerns relating to COVID subsiding, its near-term prospects haven't been looking good, either. But with the healthcare stock down more than 60% from its 52-week high of $11.36 and at a market cap of around $620 million, has the stock ...